tiprankstipranks
AN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Strong Financial Position
PremiumRatingsAN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Strong Financial Position
1M ago
AN2 Therapeutics Reports 2024 Financials and Pipeline Progress
Premium
Company Announcements
AN2 Therapeutics Reports 2024 Financials and Pipeline Progress
2M ago
AN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Stable Financial Outlook
Premium
Ratings
AN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Stable Financial Outlook
2M ago
AN2 Therapeutics submits amended EBO-301 trial statistical analysis plan to FDA
PremiumThe FlyAN2 Therapeutics submits amended EBO-301 trial statistical analysis plan to FDA
3M ago
Citizens JMP healthcare analysts hold an analyst/industry conference call
Premium
The Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
3M ago
JMP Securities healthcare analysts hold an analyst/industry conference call
Premium
The Fly
JMP Securities healthcare analysts hold an analyst/industry conference call
4M ago
AN2 Therapeutics adopts limited duration stockholder rights plan
PremiumThe FlyAN2 Therapeutics adopts limited duration stockholder rights plan
9M ago
AN2 Therapeutics reports Q2 EPS (48c), consensus (59c)
Premium
The Fly
AN2 Therapeutics reports Q2 EPS (48c), consensus (59c)
9M ago
Morning Movers: Iteris skyrockets following take-private agreement
Premium
The Fly
Morning Movers: Iteris skyrockets following take-private agreement
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100